FDA signs off on Editas CRISPR study on patients with a rare genetic disorder
The FDA gave its blessing to test a CRISPR-based therapy on patients with a rare genetic disorder that leads to blindness.
Days after a Chinese researcher incensed the world of science with , an American company is plotting a CRISPR trial of its own. But in place of the secrecy and stagecraft that marked the Chinese
